Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.

The Prostate

Wang V, Geybels MS, Jordahl KM, Gerke T, Hamid A, Penney KL, Markt SC, Freedman M, Pomerantz M, Lee GM, Rana H, Börnigen D, Rebbeck TR, Huttenhower C, Eeles RA, Stanford JL, Consortium P, Berndt SI, Claessens F, Sørensen KD, Park JY, Vega A, Usmani N, Mucci L, Sweeney CJ.
PMID: 33956343
Prostate. 2021 Jul;81(10):683-693. doi: 10.1002/pros.24148. Epub 2021 May 06.

BACKGROUND: Inflammation and one of its mediators, NF-kappa B (NFκB), have been implicated in prostate cancer carcinogenesis. We assessed whether germline polymorphisms associated with NFκB are associated with the risk of developing lethal disease (metastases or death from prostate...

Cite
Wang V, Geybels MS, Jordahl KM, et al. A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. Prostate. 2021;81(10):683-693doi: 10.1002/pros.24148.
Wang, V., Geybels, M. S., Jordahl, K. M., Gerke, T., Hamid, A., Penney, K. L., Markt, S. C., Freedman, M., Pomerantz, M., Lee, G. M., Rana, H., Börnigen, D., Rebbeck, T. R., Huttenhower, C., Eeles, R. A., Stanford, J. L., Consortium, P., Berndt, S. I., Claessens, F., Sørensen, K. D., Park, J. Y., Vega, A., Usmani, N., Mucci, L., & Sweeney, C. J. (2021). A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. The Prostate, 81(10), 683-693. https://doi.org/10.1002/pros.24148
Wang, Victoria, et al. "A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer." The Prostate vol. 81,10 (2021): 683-693. doi: https://doi.org/10.1002/pros.24148
Wang V, Geybels MS, Jordahl KM, Gerke T, Hamid A, Penney KL, Markt SC, Freedman M, Pomerantz M, Lee GM, Rana H, Börnigen D, Rebbeck TR, Huttenhower C, Eeles RA, Stanford JL, Consortium P, Berndt SI, Claessens F, Sørensen KD, Park JY, Vega A, Usmani N, Mucci L, Sweeney CJ. A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. Prostate. 2021 Jul;81(10):683-693. doi: 10.1002/pros.24148. Epub 2021 May 06. PMID: 33956343; PMCID: PMC8491321.
Copy Download .nbib Format: NLM
Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer.

Molecular & cellular oncology

Priolo C, Loda M.
PMID: 27308491
Mol Cell Oncol. 2015 Jan 23;2(4):e1001197. doi: 10.1080/23723556.2014.1001197. eCollection 2015.

Oncogene-associated metabolic signatures in prostate cancer, identified by an integrative analysis of cultured cells and murine and human tumors, suggest that AKT activation results in a glycolytic phenotype whereas MYC induces aberrant lipid metabolism. Heterogeneity in human tumors makes...

Cite
Priolo C, Loda M. Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer. Mol Cell Oncol. 2015;2(4):e1001197doi: 10.1080/23723556.2014.1001197.
Priolo, C., & Loda, M. (2015). Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer. Molecular & cellular oncology, 2(4), e1001197. https://doi.org/10.1080/23723556.2014.1001197
Priolo, Carmen, and Loda, Massimo. "Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer." Molecular & cellular oncology vol. 2,4 (2015): e1001197. doi: https://doi.org/10.1080/23723556.2014.1001197
Priolo C, Loda M. Untargeted metabolomics for profiling oncogene-specific metabolic signatures of prostate cancer. Mol Cell Oncol. 2015 Jan 23;2(4):e1001197. doi: 10.1080/23723556.2014.1001197. eCollection 2015. PMID: 27308491; PMCID: PMC4905328.
Copy Download .nbib Format: NLM
When fat goes down, prostate cancer is on the ropes.

Molecular & cellular oncology

Zadra G, Loda M.
PMID: 31131311
Mol Cell Oncol. 2019 Apr 16;6(3):1595308. doi: 10.1080/23723556.2019.1595308. eCollection 2019.

Reprogrammed lipid metabolism and persistent androgen receptor signaling commonly mark aggressive prostate cancer. We describe that targeting

Cite
Zadra G, Loda M. When fat goes down, prostate cancer is on the ropes. Mol Cell Oncol. 2019;6(3):1595308doi: 10.1080/23723556.2019.1595308.
Zadra, G., & Loda, M. (2019). When fat goes down, prostate cancer is on the ropes. Molecular & cellular oncology, 6(3), 1595308. https://doi.org/10.1080/23723556.2019.1595308
Zadra, Giorgia, and Loda, Massimo. "When fat goes down, prostate cancer is on the ropes." Molecular & cellular oncology vol. 6,3 (2019): 1595308. doi: https://doi.org/10.1080/23723556.2019.1595308
Zadra G, Loda M. When fat goes down, prostate cancer is on the ropes. Mol Cell Oncol. 2019 Apr 16;6(3):1595308. doi: 10.1080/23723556.2019.1595308. eCollection 2019. PMID: 31131311; PMCID: PMC6512936.
Copy Download .nbib Format: NLM
Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays.

eLife

Stopsack KH, Tyekucheva S, Wang M, Gerke TA, Vaselkiv JB, Penney KL, Kantoff PW, Finn SP, Fiorentino M, Loda M, Lotan TL, Parmigiani G, Mucci LA.
PMID: 34939926
Elife. 2021 Dec 23;10. doi: 10.7554/eLife.71265. Epub 2021 Dec 23.

Tissue microarrays (TMAs) have been used in thousands of cancer biomarker studies. To what extent batch effects, measurement error in biomarker levels between slides, affects TMA-based studies has not been assessed systematically. We evaluated 20 protein biomarkers on 14...

Cite
Stopsack KH, Tyekucheva S, Wang M, et al. Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. Elife. 2021;10doi: 10.7554/eLife.71265.
Stopsack, K. H., Tyekucheva, S., Wang, M., Gerke, T. A., Vaselkiv, J. B., Penney, K. L., Kantoff, P. W., Finn, S. P., Fiorentino, M., Loda, M., Lotan, T. L., Parmigiani, G., & Mucci, L. A. (2021). Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. eLife, 10. https://doi.org/10.7554/eLife.71265
Stopsack, Konrad H, et al. "Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays." eLife vol. 10 (2021). doi: https://doi.org/10.7554/eLife.71265
Stopsack KH, Tyekucheva S, Wang M, Gerke TA, Vaselkiv JB, Penney KL, Kantoff PW, Finn SP, Fiorentino M, Loda M, Lotan TL, Parmigiani G, Mucci LA. Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. Elife. 2021 Dec 23;10. doi: 10.7554/eLife.71265. Epub 2021 Dec 23. PMID: 34939926.
Copy Download .nbib Format: NLM
Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays.

eLife

Stopsack KH, Tyekucheva S, Wang M, Gerke TA, Vaselkiv JB, Penney KL, Kantoff PW, Finn SP, Fiorentino M, Loda M, Lotan TL, Parmigiani G, Mucci LA.
PMID: 34939926
Elife. 2021 Dec 23;10. doi: 10.7554/eLife.71265. Epub 2021 Dec 23.

Tissue microarrays (TMAs) have been used in thousands of cancer biomarker studies. To what extent batch effects, measurement error in biomarker levels between slides, affects TMA-based studies has not been assessed systematically. We evaluated 20 protein biomarkers on 14...

Cite
Stopsack KH, Tyekucheva S, Wang M, et al. Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. Elife. 2021;10doi: 10.7554/eLife.71265.
Stopsack, K. H., Tyekucheva, S., Wang, M., Gerke, T. A., Vaselkiv, J. B., Penney, K. L., Kantoff, P. W., Finn, S. P., Fiorentino, M., Loda, M., Lotan, T. L., Parmigiani, G., & Mucci, L. A. (2021). Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. eLife, 10. https://doi.org/10.7554/eLife.71265
Stopsack, Konrad H, et al. "Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays." eLife vol. 10 (2021). doi: https://doi.org/10.7554/eLife.71265
Stopsack KH, Tyekucheva S, Wang M, Gerke TA, Vaselkiv JB, Penney KL, Kantoff PW, Finn SP, Fiorentino M, Loda M, Lotan TL, Parmigiani G, Mucci LA. Extent, impact, and mitigation of batch effects in tumor biomarker studies using tissue microarrays. Elife. 2021 Dec 23;10. doi: 10.7554/eLife.71265. Epub 2021 Dec 23. PMID: 34939926.
Copy Download .nbib Format: NLM
Challenging Roadblocks to Cancer Cure.

Cancer research

Loda M.
PMID: 27520451
Cancer Res. 2016 Sep 01;76(17):4924-30. doi: 10.1158/0008-5472.CAN-16-1443. Epub 2016 Aug 12.

The Pezcoller Symposium in Trento, Italy, June 2015, focused entirely on the question of why advanced cancer cure is so uncommon despite the extraordinarily rapid growth of invaluable therapeutic information. Participants were asked to define and to critically evaluate...

Cite
Loda M. Challenging Roadblocks to Cancer Cure. Cancer Res. 2016;76(17):4924-30doi: 10.1158/0008-5472.CAN-16-1443.
Loda, M. (2016). Challenging Roadblocks to Cancer Cure. Cancer research, 76(17), 4924-30. https://doi.org/10.1158/0008-5472.CAN-16-1443
Loda, Massimo. "Challenging Roadblocks to Cancer Cure." Cancer research vol. 76,17 (2016): 4924-30. doi: https://doi.org/10.1158/0008-5472.CAN-16-1443
Loda M. Challenging Roadblocks to Cancer Cure. Cancer Res. 2016 Sep 01;76(17):4924-30. doi: 10.1158/0008-5472.CAN-16-1443. Epub 2016 Aug 12. PMID: 27520451.
Copy Download .nbib Format: NLM
The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study.

Cancer & metabolism

Kelly RS, Sinnott JA, Rider JR, Ebot EM, Gerke T, Bowden M, Pettersson A, Loda M, Sesso HD, Kantoff PW, Martin NE, Giovannucci EL, Tyekucheva S, Heiden MV, Mucci LA.
PMID: 27980733
Cancer Metab. 2016 Dec 07;4:22. doi: 10.1186/s40170-016-0161-9. eCollection 2016.

BACKGROUND: Understanding the biologic mechanisms underlying the development of lethal prostate cancer is critical for improved therapeutic and prevention strategies. In this study we explored the role of tumor metabolism in prostate cancer progression using mRNA expression profiling of...

Cite
Kelly RS, Sinnott JA, Rider JR, et al. The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer Metab. 2016;4:22doi: 10.1186/s40170-016-0161-9.
Kelly, R. S., Sinnott, J. A., Rider, J. R., Ebot, E. M., Gerke, T., Bowden, M., Pettersson, A., Loda, M., Sesso, H. D., Kantoff, P. W., Martin, N. E., Giovannucci, E. L., Tyekucheva, S., Heiden, M. V., & Mucci, L. A. (2016). The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer & metabolism, 422. https://doi.org/10.1186/s40170-016-0161-9
Kelly, Rachel S, et al. "The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study." Cancer & metabolism vol. 4 (2016): 22. doi: https://doi.org/10.1186/s40170-016-0161-9
Kelly RS, Sinnott JA, Rider JR, Ebot EM, Gerke T, Bowden M, Pettersson A, Loda M, Sesso HD, Kantoff PW, Martin NE, Giovannucci EL, Tyekucheva S, Heiden MV, Mucci LA. The role of tumor metabolism as a driver of prostate cancer progression and lethal disease: results from a nested case-control study. Cancer Metab. 2016 Dec 07;4:22. doi: 10.1186/s40170-016-0161-9. eCollection 2016. PMID: 27980733; PMCID: PMC5142400.
Copy Download .nbib Format: NLM
Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses.

Journal of cancer epidemiology

Melvin JC, Holmberg L, Rohrmann S, Loda M, Van Hemelrijck M.
PMID: 23401687
J Cancer Epidemiol. 2013;2013:823849. doi: 10.1155/2013/823849. Epub 2013 Jan 20.

The objective here was to summarize the evidence for, and quantify the link between, serum markers of lipid metabolism and risk of obesity-related cancers. PubMed and Embase were searched using predefined inclusion criteria to conduct meta-analyses on the association...

Cite
Melvin JC, Holmberg L, Rohrmann S, et al. Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J Cancer Epidemiol. 2013;2013:823849doi: 10.1155/2013/823849.
Melvin, J. C., Holmberg, L., Rohrmann, S., Loda, M., & Van Hemelrijck, M. (2013). Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. Journal of cancer epidemiology, 2013823849. https://doi.org/10.1155/2013/823849
Melvin, Jennifer C, et al. "Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses." Journal of cancer epidemiology vol. 2013 (2013): 823849. doi: https://doi.org/10.1155/2013/823849
Melvin JC, Holmberg L, Rohrmann S, Loda M, Van Hemelrijck M. Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J Cancer Epidemiol. 2013;2013:823849. doi: 10.1155/2013/823849. Epub 2013 Jan 20. PMID: 23401687; PMCID: PMC3563167.
Copy Download .nbib Format: NLM
Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum.

Molecular cancer research : MCR

Penney KL, Tyekucheva S, Rosenthal J, El Fandy H, Carelli R, Borgstein S, Zadra G, Fanelli GN, Stefanizzi L, Giunchi F, Pomerantz M, Peisch S, Coulson H, Lis R, Kibel AS, Fiorentino M, Umeton R, Loda M.
PMID: 33168599
Mol Cancer Res. 2021 Mar;19(3):475-484. doi: 10.1158/1541-7786.MCR-20-0548. Epub 2020 Nov 09.

Gleason score, a measure of prostate tumor differentiation, is the strongest predictor of lethal prostate cancer at the time of diagnosis. Metabolomic profiling of tumor and of patient serum could identify biomarkers of aggressive disease and lead to the...

Cite
Penney KL, Tyekucheva S, Rosenthal J, et al. Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. Mol Cancer Res. 2020;19(3):475-484doi: 10.1158/1541-7786.MCR-20-0548.
Penney, K. L., Tyekucheva, S., Rosenthal, J., El Fandy, H., Carelli, R., Borgstein, S., Zadra, G., Fanelli, G. N., Stefanizzi, L., Giunchi, F., Pomerantz, M., Peisch, S., Coulson, H., Lis, R., Kibel, A. S., Fiorentino, M., Umeton, R., & Loda, M. (2021). Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. Molecular cancer research : MCR, 19(3), 475-484. https://doi.org/10.1158/1541-7786.MCR-20-0548
Penney, Kathryn L, et al. "Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum." Molecular cancer research : MCR vol. 19,3 (2021): 475-484. doi: https://doi.org/10.1158/1541-7786.MCR-20-0548
Penney KL, Tyekucheva S, Rosenthal J, El Fandy H, Carelli R, Borgstein S, Zadra G, Fanelli GN, Stefanizzi L, Giunchi F, Pomerantz M, Peisch S, Coulson H, Lis R, Kibel AS, Fiorentino M, Umeton R, Loda M. Metabolomics of Prostate Cancer Gleason Score in Tumor Tissue and Serum. Mol Cancer Res. 2021 Mar;19(3):475-484. doi: 10.1158/1541-7786.MCR-20-0548. Epub 2020 Nov 09. PMID: 33168599; PMCID: PMC8369519.
Copy Download .nbib Format: NLM
Association of prostate cancer risk variants with gene expression in normal and tumor tissue.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Penney KL, Sinnott JA, Tyekucheva S, Gerke T, Shui IM, Kraft P, Sesso HD, Freedman ML, Loda M, Mucci LA, Stampfer MJ.
PMID: 25371445
Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):255-60. doi: 10.1158/1055-9965.EPI-14-0694-T. Epub 2014 Nov 04.

BACKGROUND: Numerous germline genetic variants are associated with prostate cancer risk, but their biologic role is not well understood. One possibility is that these variants influence gene expression in prostate tissue. We therefore examined the association of prostate cancer...

Cite
Penney KL, Sinnott JA, Tyekucheva S, et al. Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev. 2014;24(1):255-60doi: 10.1158/1055-9965.EPI-14-0694-T.
Penney, K. L., Sinnott, J. A., Tyekucheva, S., Gerke, T., Shui, I. M., Kraft, P., Sesso, H. D., Freedman, M. L., Loda, M., Mucci, L. A., & Stampfer, M. J. (2015). Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 24(1), 255-60. https://doi.org/10.1158/1055-9965.EPI-14-0694-T
Penney, Kathryn L, et al. "Association of prostate cancer risk variants with gene expression in normal and tumor tissue." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 24,1 (2015): 255-60. doi: https://doi.org/10.1158/1055-9965.EPI-14-0694-T
Penney KL, Sinnott JA, Tyekucheva S, Gerke T, Shui IM, Kraft P, Sesso HD, Freedman ML, Loda M, Mucci LA, Stampfer MJ. Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):255-60. doi: 10.1158/1055-9965.EPI-14-0694-T. Epub 2014 Nov 04. PMID: 25371445; PMCID: PMC4294966.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries